All In Biotech

Drug Trial Radar · NCT05413668

First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent

A Single Center, Double-Blinded, Phase 1a Randomized Study to Evaluate Safety and Pharmacokinetics of a New Manganese Based Magnetic Resonance Imaging (MRI) Contrast Agent, RVP-001, in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Apr 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

May 18, 2022

Primary completion

Jul 22, 2022

Study completion Aug 22, 2022

Sponsor

Lead sponsor
Reveal Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI); Quotient Sciences
First posted
Jun 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objectives of this trial are: 1. To evaluate the safety and tolerability of single ascending doses of RVP-001 in healthy adult volunteers 2. To determine the pharmacokinetics and elimination of RVP-001 in healthy adult volunteers.

Conditions

  • Healthy

Interventions

  • RVP-001Drug

    Intravenous administration of RVP-001

  • PlaceboDrug

    Intravenous administration of saline placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK) Parameter CmaxTime frame: pre-dose, 2, 5, 10, 20, 30 min and 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post-dose
  2. PK Parameter TmaxTime frame: pre-dose, 2, 5, 10, 20, 30 min and 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post-dose
  3. PK Parameter t1/2Time frame: pre-dose, 2, 5, 10, 20, 30 min and 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post-dose
  4. PK Parameter ClTime frame: pre-dose, 2, 5, 10, 20, 30 min and 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post-dose
  5. PK Parameter VdTime frame: pre-dose, 2, 5, 10, 20, 30 min and 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.